NCT07404644

An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)

Vonvendi Intravenous Specified Drug Use-results Survey "Pediatric Administration"

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 13 (estimated)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 17 Years
• Healthy volunteers: Not accepted

Summary

This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF). During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.

Conditions

• Von Willebrand Disease (vWD)

Interventions

Type	Name	Description
DRUG	vonicog alfa (rVWF)	rVWF administered by intravenous injection.

Timeline

• Start date: 2026-02-19
• Primary completion: 2031-05-30
• Completion: 2031-05-30
• First posted: 2026-02-11
• Last updated: 2026-02-23

Locations

1 site across 1 country: Japan